165 related articles for article (PubMed ID: 38811592)
1. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.
Bektaş M; Yüce S; Ay M; Uyar MH; Önder ME; Kılıç Mİ
Inflammopharmacology; 2023 Apr; 31(2):787-797. PubMed ID: 36707494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
[TBL] [Abstract][Full Text] [Related]
4. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
6. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
7. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
[TBL] [Abstract][Full Text] [Related]
8. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
11. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort.
Ward A; Sarraju A; Lee D; Bhasin K; Gad S; Beetel R; Chang S; Bonafede M; Rodriguez F; Dash R
PLoS One; 2022; 17(1):e0261786. PubMed ID: 35020742
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.
Bektaş M; Ay M; Hamdi Uyar M; İkbal Kılıç M
Int Immunopharmacol; 2024 Mar; 129():111586. PubMed ID: 38309091
[TBL] [Abstract][Full Text] [Related]
15. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
Franzetti M; Forastieri A; Borsa N; Pandolfo A; Molteni C; Borghesi L; Pontiggia S; Evasi G; Guiotto L; Erba M; Pozzetti U; Ronchetti A; Valsecchi L; Castaldo G; Longoni E; Colombo D; Soncini M; Crespi S; Maggiolini S; Guzzon D; Piconi S
J Immunol; 2021 Apr; 206(7):1569-1575. PubMed ID: 33547169
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Vanassche T; Engelen MM; Van Thillo Q; Wauters J; Gunst J; Wouters C; Vandenbriele C; Rex S; Liesenborghs L; Wilmer A; Meersseman P; Van den Berghe G; Dauwe D; Verbeke G; Thomeer M; Fivez T; Mesotten D; Ruttens D; Heytens L; Dapper I; Tuyls S; De Tavernier B; Verhamme P;
Trials; 2020 Dec; 21(1):1005. PubMed ID: 33298149
[TBL] [Abstract][Full Text] [Related]
17. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
18. Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study.
Çakmak R; Bektaş M
Infect Dis Clin Microbiol; 2024 Mar; 6(1):32-43. PubMed ID: 38633444
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
[TBL] [Abstract][Full Text] [Related]
20. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
